Targeted therapy after complete resection of metastatic lesions in metastatic renal cell carcinoma

Yong Hyun Park, Jin Woo Jung, Byung Ki Lee, Sangchul Lee, Seong Jin Jeong, Seok Soo Byun, Sang Eun Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives: To evaluate the efficacy of targeted therapy after complete resection of metastatic lesions in patients with metastatic renal cell carcinoma. Methods: We retrospectively reviewed the medical records of 53 patients with metastatic renal cell carcinoma who underwent complete surgical resection of metastatic lesions between January 2006 and December 2012. Immediate postoperative targeted therapy was given to a subgroup of patients. Progression-free survival and cancer-specific survival were assessed. Results: All patients underwent curative surgery for a primary tumor. A total of 13 patients (24.5%) had metastatic disease at initial diagnosis, and 49 (92.5%) had single-organ involvement at the time of first metastasis. None of the patients met the poor-risk criteria. Of the 19 patients who received immediate postoperative targeted therapy, five (26.3%) experienced relapse. Of the 34 patients who did not receive immediate postoperative targeted therapy, 27 (79.4%) experienced disease recurrence. Targeted therapy was restarted in 30 patients (93.8%) after relapse with excellent disease control rates (complete response: 3.3%, partial response: 36.7%, stable disease: 46.7%). Immediate postoperative targeted therapy was associated with better median progression-free survival (not reached vs 20.0months; P=0.017), but not better cancer-specific survival. Conclusions: Postoperative targeted therapy after complete metastasectomy seems to be associated with better progression-free survival in patients with metastatic renal cell carcinoma, but not with cancer-specific survival.

Original languageEnglish
Pages (from-to)153-157
Number of pages5
JournalInternational Journal of Urology
Volume22
Issue number2
DOIs
StatePublished - 1 Feb 2015

Fingerprint

Renal Cell Carcinoma
Disease-Free Survival
Therapeutics
Recurrence
Survival
Neoplasms
Metastasectomy
Medical Records
Neoplasm Metastasis

Keywords

  • Immediate postoperative targeted therapy
  • Metastasectomy
  • Metastatic renal cell carcinoma

Cite this

@article{7b0e801e63de40f798b3d95b9f02aab9,
title = "Targeted therapy after complete resection of metastatic lesions in metastatic renal cell carcinoma",
abstract = "Objectives: To evaluate the efficacy of targeted therapy after complete resection of metastatic lesions in patients with metastatic renal cell carcinoma. Methods: We retrospectively reviewed the medical records of 53 patients with metastatic renal cell carcinoma who underwent complete surgical resection of metastatic lesions between January 2006 and December 2012. Immediate postoperative targeted therapy was given to a subgroup of patients. Progression-free survival and cancer-specific survival were assessed. Results: All patients underwent curative surgery for a primary tumor. A total of 13 patients (24.5{\%}) had metastatic disease at initial diagnosis, and 49 (92.5{\%}) had single-organ involvement at the time of first metastasis. None of the patients met the poor-risk criteria. Of the 19 patients who received immediate postoperative targeted therapy, five (26.3{\%}) experienced relapse. Of the 34 patients who did not receive immediate postoperative targeted therapy, 27 (79.4{\%}) experienced disease recurrence. Targeted therapy was restarted in 30 patients (93.8{\%}) after relapse with excellent disease control rates (complete response: 3.3{\%}, partial response: 36.7{\%}, stable disease: 46.7{\%}). Immediate postoperative targeted therapy was associated with better median progression-free survival (not reached vs 20.0months; P=0.017), but not better cancer-specific survival. Conclusions: Postoperative targeted therapy after complete metastasectomy seems to be associated with better progression-free survival in patients with metastatic renal cell carcinoma, but not with cancer-specific survival.",
keywords = "Immediate postoperative targeted therapy, Metastasectomy, Metastatic renal cell carcinoma",
author = "Park, {Yong Hyun} and Jung, {Jin Woo} and Lee, {Byung Ki} and Sangchul Lee and Jeong, {Seong Jin} and Byun, {Seok Soo} and Lee, {Sang Eun}",
year = "2015",
month = "2",
day = "1",
doi = "10.1111/iju.12662",
language = "English",
volume = "22",
pages = "153--157",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",

}

Targeted therapy after complete resection of metastatic lesions in metastatic renal cell carcinoma. / Park, Yong Hyun; Jung, Jin Woo; Lee, Byung Ki; Lee, Sangchul; Jeong, Seong Jin; Byun, Seok Soo; Lee, Sang Eun.

In: International Journal of Urology, Vol. 22, No. 2, 01.02.2015, p. 153-157.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Targeted therapy after complete resection of metastatic lesions in metastatic renal cell carcinoma

AU - Park, Yong Hyun

AU - Jung, Jin Woo

AU - Lee, Byung Ki

AU - Lee, Sangchul

AU - Jeong, Seong Jin

AU - Byun, Seok Soo

AU - Lee, Sang Eun

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Objectives: To evaluate the efficacy of targeted therapy after complete resection of metastatic lesions in patients with metastatic renal cell carcinoma. Methods: We retrospectively reviewed the medical records of 53 patients with metastatic renal cell carcinoma who underwent complete surgical resection of metastatic lesions between January 2006 and December 2012. Immediate postoperative targeted therapy was given to a subgroup of patients. Progression-free survival and cancer-specific survival were assessed. Results: All patients underwent curative surgery for a primary tumor. A total of 13 patients (24.5%) had metastatic disease at initial diagnosis, and 49 (92.5%) had single-organ involvement at the time of first metastasis. None of the patients met the poor-risk criteria. Of the 19 patients who received immediate postoperative targeted therapy, five (26.3%) experienced relapse. Of the 34 patients who did not receive immediate postoperative targeted therapy, 27 (79.4%) experienced disease recurrence. Targeted therapy was restarted in 30 patients (93.8%) after relapse with excellent disease control rates (complete response: 3.3%, partial response: 36.7%, stable disease: 46.7%). Immediate postoperative targeted therapy was associated with better median progression-free survival (not reached vs 20.0months; P=0.017), but not better cancer-specific survival. Conclusions: Postoperative targeted therapy after complete metastasectomy seems to be associated with better progression-free survival in patients with metastatic renal cell carcinoma, but not with cancer-specific survival.

AB - Objectives: To evaluate the efficacy of targeted therapy after complete resection of metastatic lesions in patients with metastatic renal cell carcinoma. Methods: We retrospectively reviewed the medical records of 53 patients with metastatic renal cell carcinoma who underwent complete surgical resection of metastatic lesions between January 2006 and December 2012. Immediate postoperative targeted therapy was given to a subgroup of patients. Progression-free survival and cancer-specific survival were assessed. Results: All patients underwent curative surgery for a primary tumor. A total of 13 patients (24.5%) had metastatic disease at initial diagnosis, and 49 (92.5%) had single-organ involvement at the time of first metastasis. None of the patients met the poor-risk criteria. Of the 19 patients who received immediate postoperative targeted therapy, five (26.3%) experienced relapse. Of the 34 patients who did not receive immediate postoperative targeted therapy, 27 (79.4%) experienced disease recurrence. Targeted therapy was restarted in 30 patients (93.8%) after relapse with excellent disease control rates (complete response: 3.3%, partial response: 36.7%, stable disease: 46.7%). Immediate postoperative targeted therapy was associated with better median progression-free survival (not reached vs 20.0months; P=0.017), but not better cancer-specific survival. Conclusions: Postoperative targeted therapy after complete metastasectomy seems to be associated with better progression-free survival in patients with metastatic renal cell carcinoma, but not with cancer-specific survival.

KW - Immediate postoperative targeted therapy

KW - Metastasectomy

KW - Metastatic renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84922618024&partnerID=8YFLogxK

U2 - 10.1111/iju.12662

DO - 10.1111/iju.12662

M3 - Article

C2 - 25421791

AN - SCOPUS:84922618024

VL - 22

SP - 153

EP - 157

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 2

ER -